VYXEOS provides a limited duration of therapy, which allows patients time off from sAML treatment1,a
Dosing includes up to 2 cycles of induction and up to 2 cycles of consolidation1
The majority of patients received induction with VYXEOS in an inpatient setting during the Phase 3 trial2
Administer first consolidation cycle 5 to 8 weeks after the start of the last induction1
Of the 49 patients who received first consolidation with VYXEOS, 51% (n=25) received consolidation in an outpatient setting during the Phase 3 trial3
Learn the patient factors to consider for outpatient administration with VYXEOS
Dosing considerations
- Prior to initiating each cycle, calculate the prior cumulative anthracycline exposure for the patient1
- Assess cardiac function, complete blood counts, and liver and renal function before each consolidation cycle1
- Do not start consolidation until the absolute neutrophil count (ANC) recovers to greater than 0.5 Gi/L and the platelet count recovers to greater than 50 Gi/L in the absence of unacceptable toxicity1
- All infusions administered intravenously.1